{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T13:21:25Z","timestamp":1750166485030,"version":"3.37.3"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T00:00:00Z","timestamp":1571270400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T00:00:00Z","timestamp":1571270400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s00520-019-05080-w","type":"journal-article","created":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T14:59:18Z","timestamp":1571324358000},"page":"2637-2649","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Trends in the use of primary prophylactic colony-stimulating factors and neutropenia-related hospitalization in elderly cancer patients receiving myelosuppressive chemotherapy in the USA: 1995\u20132015"],"prefix":"10.1007","volume":"28","author":[{"given":"Shuling","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiannong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haifeng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prasad L.","family":"Gawade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark E.","family":"Bensink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Chandler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,17]]},"reference":[{"key":"5080_CR1","doi-asserted-by":"publisher","first-page":"649","DOI":"10.6004\/jnccn.2006.0056","volume":"4","author":"RE Smith","year":"2006","unstructured":"Smith RE (2006) Trends in recommendations for myelosuppressive chemotherapy for the treatment of solid tumors. J Natl Compr Cancer Netw 4:649\u2013658","journal-title":"J Natl Compr Cancer Netw"},{"key":"5080_CR2","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1200\/JCO.2011.40.1273","volume":"30","author":"SH Giordano","year":"2012","unstructured":"Giordano SH, Lin YL, Kuo YF, Hortobagyi GN, Goodwin JS (2012) Decline in the use of anthracyclines for breast cancer. J Clin Oncol 30:2232\u20132239","journal-title":"J Clin Oncol"},{"key":"5080_CR3","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jamaoncol.2018.1660","volume":"4","author":"J Marquart","year":"2018","unstructured":"Marquart J, Chen EY, Prasad V (2018) Estimation of the percentage of us patients with cancer who benefit from genome-driven oncology. JAMA Oncol 4:1093\u20131098","journal-title":"JAMA Oncol"},{"key":"5080_CR4","doi-asserted-by":"publisher","first-page":"109","DOI":"10.6004\/jnccn.2008.0012","volume":"6","author":"J Crawford","year":"2008","unstructured":"Crawford J, Dale DC, Kuderer NM, Culakova E, Poniewierski MS, Wolff D, Lyman GH (2008) Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Cancer Netw 6:109\u2013118","journal-title":"J Natl Compr Cancer Netw"},{"key":"5080_CR5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3816\/SCT.2003.n.002","volume":"1","author":"GH Lyman","year":"2003","unstructured":"Lyman GH, Kuderer NM (2003) Epidemiology of febrile neutropenia. Support Cancer Ther 1:23\u201335","journal-title":"Support Cancer Ther"},{"key":"5080_CR6","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1002\/cncr.21847","volume":"106","author":"NM Kuderer","year":"2006","unstructured":"Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106:2258\u20132266","journal-title":"Cancer"},{"key":"5080_CR7","doi-asserted-by":"publisher","first-page":"5555","DOI":"10.1002\/cncr.25332","volume":"116","author":"GH Lyman","year":"2010","unstructured":"Lyman GH, Michels SL, Reynolds MW, Barron R, Tomic KS, Yu J (2010) Risk of mortality in patients with cancer who experience febrile neutropenia. Cancer 116:5555\u20135563","journal-title":"Cancer"},{"key":"5080_CR8","doi-asserted-by":"publisher","first-page":"859","DOI":"10.3892\/etm.2011.312","volume":"2","author":"MB Schilling","year":"2011","unstructured":"Schilling MB, Parks C, Deeter RG (2011) Costs and outcomes associated with hospitalized cancer patients with neutropenic complications: a retrospective study. Exp Ther Med 2:859\u2013866","journal-title":"Exp Ther Med"},{"key":"5080_CR9","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1002\/cncr.20983","volume":"103","author":"V Caggiano","year":"2005","unstructured":"Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT (2005) Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 103:1916\u20131924","journal-title":"Cancer"},{"key":"5080_CR10","doi-asserted-by":"publisher","first-page":"e552","DOI":"10.1200\/JOP.2016.019588","volume":"13","author":"E Tai","year":"2017","unstructured":"Tai E, Guy GP Jr, Dunbar A, Richardson LC (2017) Cost of cancer-related neutropenia or fever hospitalizations, United States, 2012. J Oncol Pract 13:e552\u2013e561","journal-title":"J Oncol Pract"},{"key":"5080_CR11","doi-asserted-by":"publisher","unstructured":"Li S, Liu J, Bowers C, Garawin T, Kim C, Bensink ME, Chandler DB (2019) Febrile neutropenia-related care and associated costs in elderly patients with breast cancer, lung cancer, or non-Hodgkin lymphoma. Support Care Cancer. \nhttps:\/\/doi.org\/10.1007\/s001090000086","DOI":"10.1007\/s001090000086"},{"key":"5080_CR12","doi-asserted-by":"publisher","first-page":"4524","DOI":"10.1200\/JCO.2003.05.002","volume":"21","author":"GH Lyman","year":"2003","unstructured":"Lyman GH, Dale DC, Crawford J (2003) Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 21:4524\u20134531","journal-title":"J Clin Oncol"},{"key":"5080_CR13","doi-asserted-by":"publisher","first-page":"4302","DOI":"10.1200\/JCO.2004.03.213","volume":"22","author":"GH Lyman","year":"2004","unstructured":"Lyman GH, Dale DC, Friedberg J, Crawford J, Fisher RI (2004) Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin\u2019s lymphoma: a nationwide study. J Clin Oncol 22:4302\u20134311","journal-title":"J Clin Oncol"},{"key":"5080_CR14","doi-asserted-by":"publisher","first-page":"99","DOI":"10.6004\/jnccn.2009.0009","volume":"7","author":"GH Lyman","year":"2009","unstructured":"Lyman GH (2009) Impact of chemotherapy dose intensity on cancer patient outcomes. J Natl Compr Cancer Netw 7:99\u2013108","journal-title":"J Natl Compr Cancer Netw"},{"key":"5080_CR15","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1002\/cncr.22939","volume":"110","author":"M Shayne","year":"2007","unstructured":"Shayne M, Culakova E, Poniewierski MS, Wolff D, Dale DC, Crawford J, Lyman GH (2007) Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy. Cancer 110:1611\u20131620","journal-title":"Cancer"},{"key":"5080_CR16","doi-asserted-by":"publisher","first-page":"5319","DOI":"10.1002\/cncr.24560","volume":"115","author":"M Shayne","year":"2009","unstructured":"Shayne M, Culakova E, Wolff D, Poniewierski MS, Dale DC, Crawford J, Lyman GH (2009) Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy. Cancer 115:5319\u20135328","journal-title":"Cancer"},{"key":"5080_CR17","doi-asserted-by":"crossref","unstructured":"Mhaskar R, Clark OA, Lyman G, Engel Ayer Botrel T, Morganti Paladini L, Djulbegovic B (2014) Colony-stimulating factors for chemotherapy-induced febrile neutropenia. Cochrane Database Syst Rev CD003039","DOI":"10.1002\/14651858.CD003039.pub2"},{"key":"5080_CR18","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1200\/JCO.2006.08.8823","volume":"25","author":"NM Kuderer","year":"2007","unstructured":"Kuderer NM, Dale DC, Crawford J, Lyman GH (2007) Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 25:3158\u20133167","journal-title":"J Clin Oncol"},{"key":"5080_CR19","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1200\/JCO.2005.09.102","volume":"23","author":"CL Vogel","year":"2005","unstructured":"Vogel CL, Wojtukiewicz MZ, Carroll RR, Tjulandin SA, Barajas-Figueroa LJ, Wiens BL, Neumann TA, Schwartzberg LS (2005) First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 23:1178\u20131184","journal-title":"J Clin Oncol"},{"key":"5080_CR20","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1056\/NEJM199107183250305","volume":"325","author":"J Crawford","year":"1991","unstructured":"Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, Kris M, Grous J, Picozzi V, Rausch G et al (1991) Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325:164\u2013170","journal-title":"N Engl J Med"},{"key":"5080_CR21","unstructured":"NCCN\u00ae Clinical Practice Guidelines in Oncology. Hematopoietic growth factors. V2.2019. National Comprehensive Cancer Network website. Available at: \nhttps:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/growthfactors.pdf\n\n. Accessed 30 May 2019"},{"key":"5080_CR22","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1093\/cid\/ciq147","volume":"52","author":"AG Freifeld","year":"2011","unstructured":"Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR, America IDSo (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52:427\u2013431","journal-title":"Clin Infect Dis"},{"key":"5080_CR23","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","volume":"33","author":"TJ Smith","year":"2015","unstructured":"Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, Goldberg JM, Khatcheressian JL, Leighl NB, Perkins CL, Somlo G, Wade JL, Wozniak AJ, Armitage JO, American Society of Clinical O (2015) Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 33:3199\u20133212","journal-title":"J Clin Oncol"},{"key":"5080_CR24","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","volume":"47","author":"MS Aapro","year":"2011","unstructured":"Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C, European Organisation for R, Treatment of C (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47:8\u201332","journal-title":"Eur J Cancer"},{"key":"5080_CR25","unstructured":"Ramsey SD, McCune JS, Blough DK, McDermott CL, Clarke L, Malin JL, Sullivan SD (2010) Colony-stimulating factor prescribing patterns in patients receiving chemotherapy for cancer. Am J Manag Care 16:678\u2013686"},{"key":"5080_CR26","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1007\/s00520-017-3720-x","volume":"25","author":"R Sosa","year":"2017","unstructured":"Sosa R, Li S, Molony JT, Liu J, Stryker S, Collins AJ (2017) Use of prophylactic growth factors and antimicrobials in elderly patients with cancer: a review of the Medicare database. Support Care Cancer 25:3123\u20133132","journal-title":"Support Care Cancer"},{"key":"5080_CR27","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1007\/s00520-016-3079-4","volume":"24","author":"LS Elting","year":"2016","unstructured":"Elting LS, Xu Y, Chavez-MacGregor M, Giordano SH (2016) Granulocyte growth factor use in elderly patients with non-Hodgkin\u2019s lymphoma in the United States: adherence to guidelines and comparative effectiveness. Support Care Cancer 24:2695\u20132706","journal-title":"Support Care Cancer"},{"key":"5080_CR28","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s00520-017-3863-9","volume":"26","author":"RK Goyal","year":"2018","unstructured":"Goyal RK, Tzivelekis S, Rothman KJ, Candrilli SD, Kaye JA (2018) Time trends in utilization of G-CSF prophylaxis and risk of febrile neutropenia in a Medicare population receiving adjuvant chemotherapy for early-stage breast cancer. Support Care Cancer 26:539\u2013548","journal-title":"Support Care Cancer"},{"key":"5080_CR29","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2147\/CLEP.S105613","volume":"9","author":"KE Mues","year":"2017","unstructured":"Mues KE, Liede A, Liu J, Wetmore JB, Zaha R, Bradbury BD, Collins AJ, Gilbertson DT (2017) Use of the Medicare database in epidemiologic and health services research: a valuable source of real-world evidence on the older and disabled populations in the US. Clin Epidemiol 9:267\u2013277","journal-title":"Clin Epidemiol"},{"key":"5080_CR30","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s00520-016-3421-x","volume":"25","author":"D Weycker","year":"2017","unstructured":"Weycker D, Li X, Tzivelekis S, Atwood M, Garcia J, Li Y, Reiner M, Lyman GH (2017) Burden of chemotherapy-induced febrile neutropenia hospitalizations in us clinical practice, by use and patterns of prophylaxis with colony-stimulating factor. Support Care Cancer 25:439\u2013447","journal-title":"Support Care Cancer"},{"key":"5080_CR31","unstructured":"NCCN\u00ae Clinical Practice Guidelines in Oncology. Myeloid growth factors. National Comprehensive Cancer Network website. Available at: \nwww.nccn.org\n\n. Accessed 30 May 2019"},{"key":"5080_CR32","doi-asserted-by":"crossref","unstructured":"Crawford J, Becker PS, Armitage JO, Blayney DW, Chavez J, Curtin P, Dinner S, Fynan T, Gojo I, Griffiths EA, Hough S, Kloth DD, Kuter DJ, Lyman GH, Mably M, Mukherjee S, Patel S, Perez LE, Poust A, Rampal R, Roy V, Rugo HS, Saad AA, Schwartzberg LS, Shayani S, Talbott M, Vadhan-Raj S, Vasu S, Wadleigh M, Westervelt P, Burns JL, Pluchino L (2017) Myeloid growth factors, Version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 15:1520\u20131541","DOI":"10.6004\/jnccn.2017.0175"},{"key":"5080_CR33","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/1472-6963-13-60","volume":"13","author":"D Weycker","year":"2013","unstructured":"Weycker D, Sofrygin O, Seefeld K, Deeter RG, Legg J, Edelsberg J (2013) Technical evaluation of methods for identifying chemotherapy-induced febrile neutropenia in healthcare claims databases. BMC Health Serv Res 13:60","journal-title":"BMC Health Serv Res"},{"key":"5080_CR34","doi-asserted-by":"publisher","first-page":"4377","DOI":"10.1007\/s00520-016-3277-0","volume":"24","author":"Y Li","year":"2016","unstructured":"Li Y, Klippel Z, Shih X, Reiner M, Wang H, Page JH (2016) Relationship between severity and duration of chemotherapy-induced neutropenia and risk of infection among patients with nonmyeloid malignancies. Support Care Cancer 24:4377\u20134383","journal-title":"Support Care Cancer"},{"key":"5080_CR35","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1634\/theoncologist.10-6-427","volume":"10","author":"GH Lyman","year":"2005","unstructured":"Lyman GH, Lyman CH, Agboola O (2005) Risk models for predicting chemotherapy-induced neutropenia. Oncologist 10:427\u2013437","journal-title":"Oncologist"},{"key":"5080_CR36","doi-asserted-by":"publisher","first-page":"e411","DOI":"10.1097\/MJT.0000000000000182","volume":"23","author":"XL Du","year":"2016","unstructured":"Du XL, Zhang Y, Hardy D (2016) Temporal and geographic variations in the receipt of colony-stimulating factors and erythropoiesis-stimulating agents in a large retrospective cohort of older women with breast cancer from 2000 to 2009. Am J Ther 23:e411\u2013e421","journal-title":"Am J Ther"},{"key":"5080_CR37","doi-asserted-by":"publisher","first-page":"e0175679","DOI":"10.1371\/journal.pone.0175679","volume":"12","author":"J Davies","year":"2017","unstructured":"Davies J, Patel M, Gridelli C, de Marinis F, Waterkamp D, McCusker ME (2017) Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: a systematic review of recently published studies. PLoS One 12:e0175679","journal-title":"PLoS One"},{"key":"5080_CR38","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1097\/JTO.0000000000000225","volume":"9","author":"C Ho","year":"2014","unstructured":"Ho C, Ramsden K, Zhai Y, Murray N, Sun S, Melosky B, Laskin J (2014) Less toxic chemotherapy improves uptake of all lines of chemotherapy in advanced non-small-cell lung cancer: a 10-year retrospective population-based review. J Thorac Oncol 9:1180\u20131186","journal-title":"J Thorac Oncol"},{"key":"5080_CR39","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1200\/JOP.2011.000360","volume":"8","author":"CM Kozma","year":"2012","unstructured":"Kozma CM, Dickson M, Chia V, Legg J, Barron R (2012) Trends in neutropenia-related inpatient events. J Oncol Pract 8:149\u2013155","journal-title":"J Oncol Pract"},{"key":"5080_CR40","doi-asserted-by":"publisher","first-page":"437","DOI":"10.2147\/CMAR.S63603","volume":"6","author":"G Cuy\u00fan Carter","year":"2014","unstructured":"Cuy\u00fan Carter G, Barrett AM, Kaye JA, Liepa AM, Winfree KB, John WJ (2014) A comprehensive review of nongenetic prognostic and predictive factors influencing the heterogeneity of outcomes in advanced non-small-cell lung cancer. Cancer Manag Res 6:437\u2013449","journal-title":"Cancer Manag Res"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-019-05080-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-019-05080-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-019-05080-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T23:25:17Z","timestamp":1602804317000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-019-05080-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,17]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["5080"],"URL":"https:\/\/doi.org\/10.1007\/s00520-019-05080-w","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"type":"print","value":"0941-4355"},{"type":"electronic","value":"1433-7339"}],"subject":[],"published":{"date-parts":[[2019,10,17]]},"assertion":[{"value":"14 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Shuling Li, Jiannong Liu, and Haifeng Guo are employees of Chronic Disease Research Group, Hennepin Healthcare Research Institute, which has received project funding from Amgen Inc. Prasad L. Gawade, Christopher Kim, Mark E. Bensink, and David Chandler are employees of and own stock in Amgen Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"Formal consent was not required as the article does not contain any studies involving human participants performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}